Clinicians

Hematologic Drug Shortage Information

Feb 06
  
2024

Drug shortages are reaching an all-time high in the United States, especially in hematology care.  ASH continues to keep members apprised of shortages as well as actively engage with Congress, federal agencies, including recent discussions with U.S. Food and Drug Administration (FDA), and other stakeholders to ensure continued access to safe and effective hematologic drugs.  Please see below the recent hematologic shortages, the Society’s actions, and ways for members to get involved.

Cancer Drug Shortage Consensus Letter:

ASH, in partnership with organizations across the cancer community, developed a consensus statement identifying the primary drivers of the persistent drug shortages crisis in the United States and proposing actionable policy solutions to protect access to critical cancer medications.

The statement outlines three priorities that require immediate action to address:

Increasing transparency across the drug supply chain

Strengthening incentives for manufacturers to invest in high-quality, redundant supply system

Stabilizing the generic drug market


Read Drug Shortage Consensus

Recent Comments to Congress and the FDA

Current Hematologic Drug Shortages

Discontinued Hematologic Drugs

Resolved Hematologic Drug Shortages

Additional Resources

ASH's Comments to Congress and the U.S. Food and Drug Administration

Media Coverage of Drug Shortages

For more information or to notify ASH of drug recalls or shortages, please contact ASH Policy and Practice Manager, Myra Masood at [email protected].